Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: Comparison with recombinant human thyrotropin-stimulated assay and imaging procedures

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 5, 2006, Pages 648-652

  Giovanella, Luca ^a   Ceriani, Luca ^a   Ghelfo, Antonella ^b   Keller, Franco ^c   Sacchi, Andrea ^d   Maffioli, Marco ^b   Spriano, Giuseppe ^e  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b OSPEDALE DI CIRCOLO   (Italy)

^c REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^d Campus SME Srl   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Differentiated thyroid cancer; Immunoradiometric assay; Recombinant human TSH; Thyroglobulin; Thyroxine

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROXINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; DRUG COST; FEMALE; FOLLOW UP; HISTOLOGY; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; ULTRASOUND;

ADOLESCENT; ADULT; AGED; CELL DIFFERENTIATION; CHILD; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN; THYROXINE;

EID: 33646709223     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.107     Document Type: Article

References (27)

1. Pacini F, DeGroot LJ. Thyroid neoplasia. In: DeGroot LJ, Jameson JL, editors. Endocrinology, 4th ed. Philadelphia: Saunders; 2001:1541-66.
2. Schlumberger M. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
3. Emerson CH, Colzani R, Braverman LE. Epithelial cell thyroid cancer and thyroid stimulating hormone - when less is more. J Clin Endocrinol Metab 1997;82:9-10.
4. Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 1998;138:249-52.
5. Spencer CA, Lo Presti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999;9:435-41.
6. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000;85:175-8.
7. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003;97:90-6.
8. Wartofsky L. Management of low-risk well-differentiated thyroid cancer based only upon thyroglobulin measurement after recombinant human thyrotropin. The rhTSH-stimulated Thyroglobulin Study Group. Thyroid 2002;12:121-34.
9. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105-12.
10. Pacini F. Follow-up of differentiated thyroid cancer. Eur J Nucl Med 2002;29(Suppl 2):S492-6.
11. Pichon MF, Basuyau JP, Gory-Delabaere G, Eche N, Daver A, Blanc-Vince MP, et al. Standards, options and recommendations for tumor markers in thyroid cancers. Bull Cancer 2001;88:775-92.
12. Weightman DR, Mallick UK, Fenwick JD, Perros P. Discordant serum thyroglobulin results generated by two classes of assay in patients with thyroid carcinoma: correlation with clinical outcome after 3 years of follow-up. Cancer 2003;98:41-7.
13. Gorges R, Brandt-Mainz K, Freudenberg L, Frilling A, Grimm W, Bockisch A. [Kontinuerliche Sensitivitätssteigerung in der Schilddrüsenkarzinom- Nachsorge im Verlauf dreier Thyreoglobulin-IMA-Generationen.] Nuklearmedizin 2003;42:157-66.
14. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, Lo Presti JS. Clinical impact of thyroglobulin (Tg) and Tg antibodies method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566-75.
15. Pacini F, Fugazzola L, Lippi F, Ceccarelli C, Centoni R, Miccoli P, et al. Detection of thyroglobulin in fine-needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab 1992;74:1401-4.
16. Pacini F, Lippi F. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement. J Endocrinol Invest 1999;22:25-9.
17. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:5686-90.
18. Morgenthaler NG, Froehlich J, Rendl J, Willnich M, Alonso C, Bergmann A, et al. Technical evaluation of a new immunoradiometric and immunoluminometric assay for thyroglobulin. Clin Chem 2002;48:1077-83.
19. Giovanella L, Ceriani L. High-sensitive human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer. Clin Chem Lab Med 2002;40:480-4.
20. Sahlmann CO, Schreivogel I, Angerstein C, Siefker U, Lehmann K, Altenvoerde G, et al. [Clinical evaluation of a new thyroglobulin immunoradiometric assay in the follow-up of differentiated thyroid carcinoma]. Nuklearmedizin 2003;42:71-7. German.
21. Bourrel F, Hoff M, Regis H, Courrier P, Caron P. Immunoradiometric assay of thyroglobulin in patients with differentiated thyroid carcinoma: need for thyroglobulin recovery test. Clin Chem Lab Med 1998;36:725-30.
22. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41.
23. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:3668-73.
24. Wang PW, Wang ST, Liu RT, Chien WY, Tung SC, Lu YC, et al. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999;84:4549-53.
25. Zophel K, Wunderlich G, Smith BR. Serum thyroglobulin measurements with a high-sensitive enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma. Thyroid 2003;13:861-5.
26. Lo Presti JS, Fatemi S. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:4508-10.
27. Rosario PW, Borges MA, Fagundes TA, Franco AC, Purish S. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxine and negative neck ultrasound? Clin Endocrinol 2005;62:121-5.